ST段抬高型心肌梗死患者循环microRNA对心血管事件的 profiling 与验证
在多中心前瞻性急性冠脉综合征队列中,1002例ST段抬高型心肌梗死(STEMI)患者中有63例在1年内发生主要心血管不良事件(MACE,定义为心源性死亡或再发心肌梗死)。通过匹配的衍生病例对照队列筛选出14个miRNA进行验证,比较63例病例与126例对照,发现3个miRNA有显著差异:MACE患者中miR-26b-5p水平降低(P=0.038),而miR-320a(P=0.047)和miR-660-5p(P=0.01)水平升高。这三个miRNA可区分病例与对照,联合应用将AUC提高至0.718,加入GRACE评分和临床模型后分别将AUC从0.679提高至0.720、从0.722提高至0.732,净重分类改善均为0.20。
要点
- 在STEMI患者中,miR-26b-5p水平降低、miR-320a和miR-660-5p水平升高与1年内MACE相关。
- 三个miRNA联合可区分MACE病例与对照,AUC为0.718。
- 将三个miRNA加入GRACE评分和临床模型可提高风险预测,净重分类改善均为0.20。
核心结论
- 这是首个在STEMI患者中对与不良心血管结局相关的miRNA进行 profiling 和验证的研究;miR-26b-5p、miR-320a和miR-660-5p可区分MACE,加入GRACE评分和临床模型后提高风险预测。
研究设计与样本
- 多中心前瞻性急性冠脉综合征队列,2168例患者中1002例为STEMI,其中63例在1年随访内发生经裁定的MACE(心源性死亡或再发心肌梗死)。
- 从匹配的衍生病例对照队列进行miRNA profiling,选出14个miRNA进行验证,比较63例病例与126例对照。
主要发现
- MACE患者中miR-26b-5p水平降低(P=0.038),miR-320a水平升高(P=0.047),miR-660-5p水平升高(P=0.01)。
- 年龄和性别校正的Cox回归中,三个miRNA区分病例与对照的AUC分别为miR-26b-5p=0.707、miR-660-5p=0.683、miR-320a=0.672;三者联合AUC提高至0.718。
- 将三个miRNA加入GRACE评分,AUC从0.679提高至0.720;加入临床模型,AUC从0.722提高至0.732;两种情况净重分类改善均为0.20。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: MicroRNAs (miRNA) are important non-coding modulators controlling patterns of gene expression. However, profiling and validation of circulating miRNA levels related to adverse cardiovascular outcome has not been performed in patients with an acute coronary syndrome (ACS). METHODS AND RESULTS: In a multicentre, prospective ACS cohort, 1002 out of 2168 patients presented with ST-segment elevation myocardial infarction (STEMI). Sixty-three STEMI patients experienced an adjudicated major cardiovascular event (MACE, defined as cardiac death or recurrent myocardial infarction) within 1 year of follow-up. From a miRNA profiling in a matched derivation case-control cohort, 14 miRNAs were selected for validation. Comparing 63 cases vs. 126 controls, 3 miRNAs were significantly differentially abundant. In patients with MACE, miR-26b-5p levels (P = 0.038) were decreased, whereas miR-320a (P = 0.047) and miR-660-5p (P = 0.01) levels were increased. MiR-26b-5p has been suggested to prevent adverse cardiomyocyte hypertrophy, whereas miR-320a promotes cardiomyocyte death and apoptosis, and miR-660-5p has been related to active platelet production. This suggests that miR-26b-5p, miR-320a, and miR-660-5p may reflect alterations of different pathophysiological pathways involved in clinical outcome after ACS. Consistently, these three miRNAs reliably discriminated cases from controls [area under the receiver-operating characteristic curve (AUC) in age- and sex-adjusted Cox regression for miR-26b-5p = 0.707, miR-660-5p = 0.683, and miR-320a =0.672]. Combination of the three miRNAs further increased AUC to 0.718. Importantly, addition of the three miRNAs to both, the Global Registry of Acute Coronary Events (GRACE) score and a clinical model increased AUC from 0.679 to 0.720 and 0.722 to 0.732, respectively, with a net reclassification improvement of 0.20 in both cases. CONCLUSION: This is the first study performing profiling and validation of miRNAs that are associated with adverse cardiovascular outcome in patients with STEMI. MiR-26b-5p, miR-320a, and miR-660-5p discriminated for MACE and increased risk prediction when added to the GRACE score and a clinical model. These findings suggest that the release of specific miRNAs into circulation may reflect the activation of molecular pathways that impact on clinical outcome after STEMI.
引用
- Jakob P, Kacprowski T, Briand-Schumacher S, et al. Profiling and validation of circulating microRNAs for cardiovascular events in patients presenting with ST-segment elevation myocardial infarction. Eur Heart J. 2017. PMID: 28011706. doi:10.1093/eurheartj/ehw563
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。